Suppr超能文献

分子标志物的鉴定及其在 CHO 生物工艺中的应用。

Molecular biomarkers identification and applications in CHO bioprocessing.

机构信息

Merck Biotech Development Center, Ares Trading SA (an affiliate of Merck KGaA, Darmstadt, Germany), Fenil-sur-Corsier, Switzerland.

Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.

出版信息

J Biotechnol. 2024 Sep 10;392:11-24. doi: 10.1016/j.jbiotec.2024.06.005. Epub 2024 Jun 8.

Abstract

Biomarkers are valuable tools in clinical research where they allow to predict susceptibility to diseases, or response to specific treatments. Likewise, biomarkers can be extremely useful in the biomanufacturing of therapeutic proteins. Indeed, constraints such as short timelines and the need to find hyper-productive cells could benefit from a data-driven approach during cell line and process development. Many companies still rely on large screening capacities to develop productive cell lines, but as they reach a limit of production, there is a need to go from empirical to rationale procedures. Similarly, during bioprocessing runs, substrate consumption and metabolism wastes are commonly monitored. None of them possess the ability to predict the culture behavior in the bioreactor. Big data driven approaches are being adapted to the study of industrial mammalian cell lines, enabled by the publication of Chinese hamster and CHO genome assemblies which allowed the use of next-generation sequencing with these cells, as well as continuous proteome and metabolome annotation. However, if these different -omics technologies contributed to the characterization of CHO cells, there is a significant effort remaining to apply this knowledge to biomanufacturing methods. The correlation of a complex phenotype such as high productivity or rapid growth to the presence or expression level of a specific biomarker could save time and effort in the screening of manufacturing cell lines or culture conditions. In this review we will first discuss the different biological molecules that can be identified and quantified in cells, their detection techniques, and associated challenges. We will then review how these markers are used during the different steps of cell line and bioprocess development, and the inherent limitations of this strategy.

摘要

生物标志物是临床研究中的有价值工具,它们可以用于预测疾病易感性或对特定治疗的反应。同样,生物标志物在治疗性蛋白质的生物制造中也非常有用。实际上,在细胞系和工艺开发过程中,由于时间紧迫和需要寻找高产细胞等限制因素,数据驱动的方法可能会受益。许多公司仍然依靠大规模筛选能力来开发高产细胞系,但随着生产达到极限,需要从经验方法转向合理的方法。同样,在生物加工过程中,通常会监测基质消耗和代谢废物。它们都没有预测生物反应器中培养行为的能力。大数据驱动的方法正在适应工业哺乳动物细胞系的研究,这得益于中国仓鼠和 CHO 基因组组装的发表,这些组装允许使用下一代测序技术对这些细胞进行测序,以及对连续的蛋白质组和代谢组进行注释。然而,如果这些不同的组学技术有助于 CHO 细胞的表征,那么仍然需要做出很大的努力将这些知识应用于生物制造方法。将复杂表型(如高生产力或快速生长)与特定生物标志物的存在或表达水平相关联,可以节省筛选制造细胞系或培养条件的时间和精力。在这篇综述中,我们将首先讨论可以在细胞中鉴定和定量的不同生物分子、它们的检测技术以及相关挑战。然后,我们将回顾这些标记物在细胞系和生物加工开发的不同步骤中是如何使用的,以及该策略的固有局限性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验